Clinico-pathological features | ||
---|---|---|
Primary tumors (n = 133*) | N (%) | |
Subtype | IBC, NOS | 114 (85.7%) |
 | Lobular | 7 (5.3%) |
 | Other special types | 7 (5.3%) |
 | Mixed | 5 (3.8%) |
Molecular subtype (IHC surrogates) | Luminal B HER2− | 68 (51.1%) |
 | Luminal B HER2+ | 6 (4.5%) |
 | HER2+ non-luminal | 1 (0.8%) |
 | Triple negative | 58 (43.6%) |
pT | 1b | 9 (6.7%) |
 | 1c | 43 (32.3%) |
 | 2 | 55 (41.4%) |
 | 3 | 17 (12.8%) |
 | 4 | 4 (3%) |
 | NA | 5 (3.8%) |
pN | 0 | 34 (25.6%) |
 | 1–3 | 80 (60.2%) |
 | NA | 19 (14.3%) |
Recurrences/metastasis (n = 135**) | N (%) | |
Site | ||
Local (n = 47) | Axillary lymph node | 24 (51.1%) |
 | Skin | 14 (29.8%) |
 | Soft tissue | 9 (19.1%) |
Distant (n = 88) | Bone | 2 (2.3%) |
 | Liver | 22 (25%) |
 | Lung | 14 (15.9%) |
 | Lymph node | 4 (4.5%) |
 | Ovary | 2 (2.3%) |
 | Pleura | 37 (42%) |
 | Skin | 3 (3.4%) |
 | Soft tissue | 4 (4.5%) |